To determine whether apparent involvement of DYRK1A in Alzheimer’s disease (AD) pathology makes it a candidate plasma biomarker for diagnosis, we developed a method to quantify plasma DYRK1A by ...

Reducing DYRK1A reduced accessibility of the chromatin near the ACE2 transcriptional start site, along with several other sites that are known to enhance activity of the ACE2 gene.

Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 Acquisition includes ...

DYRK1A inhibition shifts the balance to produce more MyD88 short form, which leads to deactivation of the downstream release of several pro-inflammatory cytokines.

Alzheimer’s disease (AD) is a neurodegenerative condition. There are currently no FDA-approved disease‐modifying therapies for AD, despite it being the most common cause of dementia. We recently spoke ...

Dyrk1a codes for an enzyme called DYRK1A. The researchers tested a DYRK1A inhibitor on mice pregnant with pups that model the hearts defects in Down syndrome, as their hearts were forming.

Research undertaken in recent years on Down syndrome has focused on the DYRK1A gene. The super-expression of this gene affects transmission in the neurons, according to Garikoitz Azkona.

Global kinome profiling reveals DYRK1A as critical activator of the human mitochondrial import machinery. Nature Communications, 2021; 12 (1) DOI: 10.1038/s41467-021-24426-9 ...

After treating Dyrk1a mice from birth to day 7, she found that was the case. The observed microcephaly improved, and under the microscope, the brain tissue showed normalized neuron growth.

FRTX-02 is a potent, highly selective, and orally bioavailable potential first-in-class DYRK1A inhibitor that aims to restore immune balance by modulating both adaptive and innate immune responses ...